SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a)...
Hence then, the article about innovent announces phase 3 credit 5 study met primary endpoint sintbilo tafolecimab injection as first line monotherapy treatment for hyperlipidemia demonstrated potent lipid lowering efficacy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy )
Also on site :
- Russia, Ukraine exchange deadly drone strikes as Zaporizhzhia nuclear plant loses power
- Toxic Homes, Terrible Dilemma: Oscar Contender ‘Still Standing’ Documents Homeowner Nightmare After LA Wildfires – SFFILM Doc Stories
- In 1885, Dr Pepper Was Born in a Texas Drugstore—141 Years Later, Hobby Lobby Is Selling a $12 T-Shirt That Celebrates Its History